Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report

被引：0
|
作者：
Zhuang, Hongkai [1 ,2 ]
Ma, Zuyi [1 ,2 ]
Wu, Yanxia [3 ]
Yin, Zi [1 ]
Jian, Zhixiang [1 ]
Zhang, Chuanzhao [1 ]
Hou, Baohua [1 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Gen Surg, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
[2] Shantou Univ, Med Coll, Shantou 515000, Peoples R China
[3] Sun Yat Sen Univ, Sch Med, Guangzhou 510080, Peoples R China
来源：
TRANSLATIONAL CANCER RESEARCH | 2020年 / 9卷 / 04期
基金：
中国国家自然科学基金;
关键词：
Castleman disease; neo-adjuvant chemotherapy; plasma cell type; case report;
D O I：
10.21037/tcr.2020.02.45
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neo-adjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHOP) chemotherapy alleviated the symptom of plasma cell type of Castleman disease (PCCD) as well as downsized the tumor to provide an opportunity for radical surgical resection. It would contribute to the treatment for borderline resectable or unresectable UCD in the future.
引用
收藏
页码：3030 / 3033
页数：4
相关论文
共 50 条
  • [41] Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline resectable pancreatic cancer: Prospective randomized study
    Tamura, Takashi
    Itonaga, Masahiro
    Ashida, Reiko
    Yamashita, Yasunobu
    Hatamaru, Keiichi
    Kawaji, Yuki
    Emori, Tomoya
    Kitahata, Yuji
    Miyazawa, Motoki
    Hirono, Seiko
    Okada, Ken-ichi
    Kawai, Manabu
    Shimokawa, Toshio
    Yamaue, Hiroki
    Kitano, Masayuki
    DIGESTIVE ENDOSCOPY, 2021, 33 (07) : 1170 - 1178
  • [42] Borderline Resectable Pancreatic Cancer Treated By Pancreaticoduodenectomy With Splenic Artery Resection (PD-SAR) After Neoadjuvant Chemotherapy: A Case Report
    Tanaka, Hideharu
    Imai, Hisashi
    Higashi, Toshiya
    Murase, Katsutoshi
    Suzui, Natsuko
    Tanaka, Yoshihiro
    Okumura, Naoki
    Matsuhashi, Nobuhisa
    Takahashi, Takao
    Yoshida, Kazuhiro
    PANCREAS, 2022, 51 (06) : 709 - 709
  • [43] Neo-adjuvant sequential chemotherapy with FEC followed by docetaxel for primary breast cancer. A phase 11 study. Interest of NMR imaging for predicting pathological response
    Focan, C.
    Graas, M.
    Kreutz, F.
    Lastra, M.
    Bourdoux, B.
    Cusumano, R.
    Dewandre, J. M.
    Weerts, J.
    Focan-Henrard, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 106 - 107
  • [44] Surgical Excision of Widespread Nodal Metastases as Neo-Adjuvant Treatment prior to PRRT for Metastatic Neuroendocrine Carcinoma of Unknown Primary - a Case Report
    Krzak, A. M.
    Patel, A.
    Jani, P.
    BRITISH JOURNAL OF SURGERY, 2019, 106 : 44 - 44
  • [45] Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors
    Bellati, F.
    Pernice, M.
    Manci, N.
    Palaia, I.
    Tomao, F.
    Marchetti, C.
    Zullo, M. A.
    Muzii, L.
    Angioli, R.
    Panici, P. Benedeth
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 722 - 729
  • [46] Superior Mesenteric Vein Resection Followed by Porto-Jejunal Anastomosis During Pancreatoduodenectomy for Borderline Resectable Pancreatic Cancer - A Case Report and Literature Review
    Bacalbasa, Nicolae
    Balescu, Irina
    Varlas, Valentin
    Dimitriu, Mihai
    Balalau, Cristian
    Furtunescu, Florentina
    Gherghiceanu, Florentina
    Radavoi, Daniel
    Diaconu, Camelia
    Stiru, Ovidiu
    Savu, Cornel
    Brasoveanu, Vladislav
    Cordos, Ioan
    IN VIVO, 2021, 35 (05): : 2975 - 2979
  • [47] Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case–control matching study
    Noor van Ginkel
    Tom J. N. Hermans
    Dennie Meijer
    Joost L. Boormans
    Jens Voortman
    Laura Mertens
    Sytse C. van Beek
    André N. Vis
    International Urology and Nephrology, 2022, 54 : 3145 - 3152
  • [48] Pemetrexed and cisplatin followed sequentially by gefitinib as neo-adjuvant therapy for stage IIB EGFR-mutation-positive lung adenocarcinoma patient: a case report and literature review
    Wang, Hongyan
    Tang, Hong
    Wang, Lifeng
    Wu, Yufeng
    Zhang, Zhe
    He, Zhen
    Wang, Lili
    Wang, Qiming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (01): : 1376 - 1384
  • [49] Does Neo-adjuvant chemotherapy response in the primary breast tumour correlate with axillary response in proven node positive ER positive HER2 negative disease?
    Borkar, N.
    Provenzano, E.
    Garreffa, E.
    Benson, J.
    Forouhi, P.
    Hugh-Davies, L.
    Wilson, C.
    McAdam, K.
    Russell, S.
    Agrawal, A.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S63 - S63
  • [50] Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study
    van Ginkel, Noor
    Hermans, Tom J. N.
    Meijer, Dennie
    Boormans, Joost L.
    Voortman, Jens
    Mertens, Laura
    van Beek, Sytse C.
    Vis, Andre N.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (12) : 3145 - 3152
12345